Source: International Congress 2016 – IPF treatment I
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Thomas O'Riordan (Seattle, United States of America), Ganesh Raghu, Kevin Brown, Harold Collard, David Lederer, Fernando Martinez, Paul Noble, Jin Woo Song, Athol Wells, Timothy Whelan, Emmanuel Moreau, Scott Patterson, Selina Bayly, Jason Chien, Jennifer Zhang, Thomas O’Riordan. LATE-BREAKING ABSTRACT: Simtuzumab in idiopathic pulmonary fibrosis: Results of a randomized clinical trial. Eur Respir J 2016; 48: Suppl. 60, 1807

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry Source: International Congress 2014 – Clinical trials in IPF Year: 2014 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014 LATE-BREAKING ABSTRACT: Bosentan in Pulmonary Hypertension associated with Fibrotic Idiopathic Interstitial Pneumonia:A Randomized, Double-Blind, Placebo-controlled Study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 LATE-BREAKING ABSTRACT: Role of trans-bronchial lung cryobiopsies in interstitial lung diseases: Preliminary results of a Belgian prospective study Source: International Congress 2016 – IPF clinical Year: 2016 Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone Source: International Congress 2016 – Orphan diseases II Year: 2016 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP) Source: International Congress 2014 – IPF and surroundings Year: 2014 Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 Pirfenidone post-authorization safety registry (PASSPORT) update Source: International Congress 2015 – Treatment of IPF Year: 2015 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON) Source: International Congress 2015 – Treatment of IPF Year: 2015 LATE-BREAKING ABSTRACT: Efficacy of inhaled N-acetylcystein in patients with interstitial pneumonia Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Clinical trials in interstitial lung disease Source: Eur Respir Mon; 2009: 46: 67–84 Year: 2009 A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2014 – IPF and surroundings Year: 2014 A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014 Lung cancer in patients with idiopathic pulmonary fibrosis: Clinical characteristics and impact on survival Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014